Search
Pivhydrazine
go.drugbank.com/drugs/DB09252ApprovedWithdrawnIn 1960, it was widely used as an antidepressant agent but it is now discontinued.
Sodium zirconium cyclosilicate
go.drugbank.com/drugs/DB14048ApprovedInvestigationalSodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that … [L2933] Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and
Xanthan gum
go.drugbank.com/drugs/DB11253ApprovedXanthan gum is a polysaccharide gum derived from* Xanthomonas campestris* by a pure-culture fermentation process and purified by recovery with isopropyl alcohol. … Xanthan gum is a direct food additive permitted for direct addition to food for human consumption by the FDA. It is used as a thickening agent and stabilizer in emulsions.
Monobenzone
go.drugbank.com/drugs/DB00600ApprovedWithdrawnIt exerts a depigmenting effect on skin of mammals by increasing the excretion of melanin from the melanocytes. It may also cause destruction of melanocytes and permanent depigmentation.
Interferon alfa-2a
go.drugbank.com/drugs/DB00034ApprovedInvestigationalWithdrawnAn oral form is being developed by Amarillo Biosciences. … This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
Tolazamide
go.drugbank.com/drugs/DB00839ApprovedA sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Chlorzoxazone
go.drugbank.com/drugs/DB00356ApprovedIt is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
Trimebutine
go.drugbank.com/drugs/DB09089ApprovedInvestigationalTrimebutine is not a FDA-approved drug, but it is available in Canada and several other international countries.
Relugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigational[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022.[L42150] Relugolix has also been studied in the symptomatic treatment of endometriosis. … It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and more recently by the United States' FDA in 2020, under the brand name
Xamoterol
go.drugbank.com/drugs/DB13781ApprovedIt modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors.